139 related articles for article (PubMed ID: 36622516)
61. Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC).
Lawrence D; Maschio M; Leahy KJ; Yunger S; Easaw JC; Weinstein MC
J Med Econ; 2013 Dec; 16(12):1387-98. PubMed ID: 24102083
[TBL] [Abstract][Full Text] [Related]
62. Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: a retrospective analysis in Southwest Chinese population.
Chen Y; Cao D; Bi F; Li Q; Qiu M
Med Oncol; 2014 May; 31(5):935. PubMed ID: 24683007
[TBL] [Abstract][Full Text] [Related]
63. Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3).
Stahler A; Heinemann V; Holch JW; von Einem JC; Westphalen CB; Heinrich K; Schlieker L; Jelas I; Alig AHS; Fischer LE; Weiss L; Modest DP; von Weikersthal LF; Decker T; Kiani A; Moehler M; Kaiser F; Kirchner T; Jung A; Stintzing S
Int J Cancer; 2021 Dec; 149(11):1935-1943. PubMed ID: 34310714
[TBL] [Abstract][Full Text] [Related]
64. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
65. Evaluation of the Cost-effectiveness of Doublet Therapy in Metastatic BRAF Variant Colorectal Cancer.
Patel KK; Stein S; Lacy J; O'Hara M; Huntington SF
JAMA Netw Open; 2021 Jan; 4(1):e2033441. PubMed ID: 33433598
[TBL] [Abstract][Full Text] [Related]
66. Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer.
Hoyle M; Peters J; Crathorne L; Jones-Hughes T; Cooper C; Napier M; Hyde C
Value Health; 2013; 16(2):288-96. PubMed ID: 23538180
[TBL] [Abstract][Full Text] [Related]
67. RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial.
Normanno N; Esposito Abate R; Lambiase M; Forgione L; Cardone C; Iannaccone A; Sacco A; Rachiglio AM; Martinelli E; Rizzi D; Pisconti S; Biglietto M; Bordonaro R; Troiani T; Latiano TP; Giuliani F; Leo S; Rinaldi A; Maiello E; Ciardiello F;
Ann Oncol; 2018 Jan; 29(1):112-118. PubMed ID: 28950295
[TBL] [Abstract][Full Text] [Related]
68. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
Mittmann N; Au HJ; Tu D; O'Callaghan CJ; Isogai PK; Karapetis CS; Zalcberg JR; Evans WK; Moore MJ; Siddiqui J; Findlay B; Colwell B; Simes J; Gibbs P; Links M; Tebbutt NC; Jonker DJ; ;
J Natl Cancer Inst; 2009 Sep; 101(17):1182-92. PubMed ID: 19666851
[TBL] [Abstract][Full Text] [Related]
69. Cost-effectiveness of biweekly cetuximab plus chemotherapy in first-line treatment for RAS wild-type metastatic colorectal cancer.
Giuliani J
J Oncol Pharm Pract; 2022 Oct; 28(7):1674-1676. PubMed ID: 35833215
[No Abstract] [Full Text] [Related]
70. KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective.
Blank PR; Moch H; Szucs TD; Schwenkglenks M
Clin Cancer Res; 2011 Oct; 17(19):6338-46. PubMed ID: 21807639
[TBL] [Abstract][Full Text] [Related]
71. Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line
Hill AG; Findlay MP; Burge ME; Jackson C; Alfonso PG; Samuel L; Ganju V; Karthaus M; Amatu A; Jeffery M; Bartolomeo MD; Bridgewater J; Coveler AL; Hidalgo M; Kapp AV; Sufan RI; McCall BB; Hanley WD; Penuel EM; Pirzkall A; Tabernero J
Clin Cancer Res; 2018 May; 24(10):2276-2284. PubMed ID: 29506988
[No Abstract] [Full Text] [Related]
72. RAS testing and cetuximab treatment for metastatic colorectal cancer: a cost-effectiveness analysis in a setting with limited health resources.
Wu B; Yao Y; Zhang K; Ma X
Oncotarget; 2017 Sep; 8(41):71164-71172. PubMed ID: 29050352
[TBL] [Abstract][Full Text] [Related]
73. A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials.
Berger MD; Ning Y; Stintzing S; Heinemann V; Cao S; Zhang W; Yang D; Miyamoto Y; Suenaga M; Schirripa M; Hanna DL; Soni S; Puccini A; Tokunaga R; Naseem M; Battaglin F; Cremolini C; Falcone A; Loupakis F; Lenz HJ
Eur J Cancer; 2020 May; 131():89-97. PubMed ID: 32305727
[TBL] [Abstract][Full Text] [Related]
74. Cetuximab and vemurafenib plus FOLFIRI (5-fluorouracil/leucovorin/irinotecan) for BRAF V600E-mutated advanced colorectal cancer (IMPROVEMENT): An open-label, single-arm, phase II trial.
Wang Z; Qin BD; Ye CY; Wang MM; Yuan LY; Dai WP; Sun L; Liu K; Qin WX; Jiao XD; Li XN; Zang YS
Eur J Cancer; 2022 Mar; 163():152-162. PubMed ID: 35074651
[TBL] [Abstract][Full Text] [Related]
75. Cost-effectiveness of cetuximab for colorectal cancer.
Park T; Choi CJ; Choi Y; Suh DC
Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):667-677. PubMed ID: 27750444
[TBL] [Abstract][Full Text] [Related]
76. KRAS mutational status assessment in patients with metastatic colorectal cancer: are the clinical implications so clear?
Hebbar M; Fournier P; Romano O
Eur J Cancer Care (Engl); 2010 Mar; 19(2):167-71. PubMed ID: 19702696
[TBL] [Abstract][Full Text] [Related]
77. Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147.
Huang J; Nair SG; Mahoney MR; Nelson GD; Shields AF; Chan E; Goldberg RM; Gill S; Kahlenberg MS; Quesenberry JT; Thibodeau SN; Smyrk TC; Grothey A; Sinicrope FA; Webb TA; Farr GH; Pockaj BA; Berenberg JL; Mooney M; Sargent DJ; Alberts SR;
Clin Colorectal Cancer; 2014 Jun; 13(2):100-9. PubMed ID: 24512953
[TBL] [Abstract][Full Text] [Related]
78. Cost-effectiveness of first-line treatments for patients with KRAS wild-type metastatic colorectal cancer.
Ewara EM; Zaric GS; Welch S; Sarma S
Curr Oncol; 2014 Aug; 21(4):e541-50. PubMed ID: 25089105
[TBL] [Abstract][Full Text] [Related]
79. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model.
Hoyle M; Crathorne L; Peters J; Jones-Hughes T; Cooper C; Napier M; Tappenden P; Hyde C
Health Technol Assess; 2013 Apr; 17(14):1-237. PubMed ID: 23547747
[TBL] [Abstract][Full Text] [Related]
80. A retrospective analysis on first-line bevacizumab, cetuximab, and panitimumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG).
Degirmencioglu S; Tanriverdi O; Menekse S; Dogan M; Hacıoglu B; Oktay E; Erdem D; Arpaci E; Uluc BO; Turhal S; Yilmaz M; Pilanci KN; Sakin A; Araz M; Cokmert S; Ozdemir O; Sen E; Nayir E
J BUON; 2019; 24(1):136-142. PubMed ID: 30941962
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]